Ganesh Veerappan, MD
Gastroenterology · Akron, OHNPI 1780650895
Payments from drug & device makers
Across 505 payments — averaging $697.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$126K
- AbbVie$74K
- Johnson & Johnson$70K
- Pfizer$39K
- Boehringer Ingelheim International GmbH$20K
- Chugai Pharmaceutical Co., Ltd.$15K
- plus $8K from 30 others
Across 2 payments — averaging $1155.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 56 | $125,974 |
| AbbVie | 178 | $74,344 |
| Johnson & Johnson | 75 | $70,385 |
| Pfizer | 75 | $38,907 |
| Boehringer Ingelheim International GmbH | 7 | $19,529 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $14,954 |
| Caris MPI, Inc. | 1 | $3,750 |
| Sanofi | 4 | $2,041 |
| Phathom Pharmaceuticals, Inc. | 6 | $327 |
| Bristol Myers Squibb | 22 | $305 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $302 |
| Shire North American Group Inc | 1 | $200 |
| Madrigal Pharmaceuticals | 7 | $159 |
| Lilly USA, LLC | 6 | $150 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $122 |
| Ardelyx, Inc. | 6 | $121 |
| Merck | 7 | $114 |
| Novo Nordisk | 1 | $113 |
| QOL Medical, LLC | 5 | $100 |
| Intercept Pharmaceuticals, Inc. | 3 | $50 |
| Nestle Healthcare Nutrition Inc. | 3 | $44 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Gilead | 2 | $36 |
| Fresenius Kabi USA, LLC | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Organon | 1 | $27 |
| Boston Scientific | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Vivus LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Dentsply IH Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
How this compares
$352,451 in reported general payments places this provider in the 90th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Akron
- Naim AlkhouriWestlake$10.1M
- Florian RiederCleveland$8.7M
- Keith FriedenbergMentor$5M
- Anita AfzaliCincinnati$2.4M
- Pierre GholamCleveland$1.9M
- Benjamin CohenCleveland$1.9M
- Mohamed NaemWestlake$1.6M
- Mousab TabbaaWestlake$1.4M
- Pradeep BekalCincinnati$1.4M
- Na LiColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.